Seroba Kernel Life Sciences confirm additional €3.3M Investment in Opsona Therapeutics.

Dublin, Ireland, 19 May 2009: Seroba Kernel Life Sciences confirmed today that the Roche Venture Fund (the corporate venturing arm of pharmaceutical company Roche) and Enterprise Ireland have invested a total of €3.3m in Seroba Kernel investee Opsona Therapeutics. This follows a syndicated investment in February 2009 bringing the total Series B financing round to €21.3m.

“Roche is excited about investing in Opsona. Opsona’s scientific founder, Professor Luke O’Neill of Trinity College Dublin, is world renowned for his expertise in Toll-like receptors and innate immunity,” said Carole Nuechterlein, Head of the Roche Venture Fund when commenting on the announcement.

Seamus O’Hara, Partner at Seroba Kernel Life Sciences added “Roche is a significant global player in the therapeutic areas of interest to Opsona and its participation in this funding round, along side the corporate venturing arms of Novartis and Genentech, represents excellent corporate validation and also adds an important source of commercial support for the company as it moves its lead products towards the clinic.” Commenting on today’s announcement John O’Dea, Head of Lifesciences in the High Potential Start Up Department in Enterprise Ireland said: “Opsona epitomises the type of innovative high potential company that EI is keen to support, and shows what can be achieved when the ambition and energy of a company are harnessed and supported. The company has a solid business strategy and strong links with industry and universities. Opsona has grown its product pipeline by investing intensively in collaborative R & D.”


< back to home page